antibody-drug conjugates

structure and mechanism of action of antibody conjugated drugs

ADC Linker-The key from mAb to ADC

Antibody conjugated drug (ADC) is a relatively complex molecule that connects a targeted antibody with a cytotoxic payload through a chemical linker. In recent years, people have gradually deepened their research on payload and […]

antibody-drug conjugates

Progress in Analysis of Neutralizing Activity of ADC Anti-drug Antibodies

Antibody drug conjugates (ADCs) are multi-domain molecules composed of monoclonal antibodies, linkers and small molecule cytotoxins. ADCs specifically bind target antigens highly expressed on the surface of tumor cells through monoclonal antibodies, enter […]

cmc

CMC Regulatory Considerations for ADCs

Antibody drug conjugates (ADCs) are a new class of biopharmaceuticals that use monoclonal antibodies to target tumor cells to deliver potent cytotoxic drugs. So far, a total of 15 ADC drugs […]

ADC payloads

Antibody-Drug Conjugates: Recent Overview of ADC Payloads

Among the first-generation ADC drugs, traditional chemotherapy drugs such as methotrexate, vinblastine, and doxorubicin were used as cytotoxic payloads. However, due to insufficient cytotoxicity and selectivity against tumor cells, the first-generation […]

ADC payloads

Antibody-Drug Conjugates: New Strategies of ADC Payloads

The concept of ADCs was first proposed by Nobel Prize winner Paul Ehrlich in 1913. But it was not until 1975, when hybridoma technology began to be used to produce monoclonal […]

ADC drugs

Quantitative Bioanalysis of Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs) are new therapies that combine the high targeting of monoclonal antibodies with the strong cytotoxicity of small molecule cytotoxins. Due to its precise and powerful mechanism of action, […]

ADCs Targeting Trop2

What are the Possibilities for ADCs Targeting Trop2?

Antibody drug conjugate (ADC) research involves more and more targets, such as HER-2, Trop-2, Claudin-18.2, B7-H3 and B7-H4, etc. Trop-2 is a transmembrane glycoprotein. Its high expression is associated with the […]

Research Progress of Dual-Loading ADCs

Antibody-drug conjugate (ADC) combines the tumor targeting specificity of monoclonal antibodies and the potent cell killing activity of cytotoxic drugs (warhead/payload), through a carefully designed chemical linker (linker). The two are […]

ADC toxicity

Effects of ADC Toxicity and Optimization Strategies

So far, the FDA and EMA have approved six ADC drugs for patients with solid tumors. Fig. 1 depicts the composition of each ADC (targeting antigen, mAb type, payload, and linker), […]

antibody drug conjugate

FDA Approved Antibody-Drug Conjugates (ADCs) By 2023

Antibody Drug Conjugate (ADC) is a complex formed by linking cytotoxic drugs to tumor-targeting monoclonal antibodies. It combines the characteristics of targeted drugs and chemotherapy drugs to achieve precise treatment. The concept […]